- Home
- DMA vs OTLK Comparison
DMA vs OTLK Comparison
Compare DMA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | OTLK |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 96.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | DMA | OTLK |
|---|---|---|
| Price | $8.98 | $1.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 34.6K | ★ 3.3M |
| Earning Date | 01-01-0001 | 12-19-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,413,535.00 |
| Revenue This Year | N/A | $2,048.59 |
| Revenue Next Year | N/A | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $0.79 |
| 52 Week High | $8.00 | $3.39 |
Technical Indicators
Market Signals| Indicator | DMA | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 47.60 |
| Support Level | $8.97 | $1.78 |
| Resistance Level | $9.15 | $2.54 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 26.09 | 18.08 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.